Eisai Hopes To Resume Trials On New Alzheimer's Drug (Japan)
This article was originally published in PharmAsia News
Executive Summary
Eisai reports it will resume clinical trials this fiscal year on E2012, the planned-for successor to its Alzheimer's drug Aricept. Eisai began phase I trials on E2012 in 2006 in the U.S., but suspended the trials earlier this year after concomitant trials in rats indicated that E2012 could cause clouding of the eyes. The drug firm has since done experiments with rats and discovered that the eye problem developed because E2012 caused blood cholesterol levels to fall too far. The tests also found that using E2012 in a lower dose kept the blood cholesterol levels from declining too much. Eisai has talked with the U.S. Food and Drug Administration and hopes to resume clinical trials before the end of the current fiscal year after finding a blood marker that can be used to monitor safety. (Click here for more - May Require Paid Subscription
You may also be interested in...
Rethinking Alzheimer's: Mapping Out an Approval Process
Drug companies involved in Alzheimer's disease research are a little fed up with FDA. Some, like Wyeth, believe the agency should put Alzheimer's research higher up on its priority list and allow the use of surrogate endpoints for clinical trials. But FDA says that no validated surrogate exists for Alzheimer's, and until it has hard data from products in development, it is loath to recommend one. A recent reorganization of the agency's neurology group may provide an opening to press home those arguments.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.